Resverlogix Corp. Asset Resilience Ratio
Resverlogix Corp. asset resilience ratio. Resverlogix Corp. (RVX) has an Asset Resilience Ratio of 0.00% as of June 2009. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RVX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Resverlogix Corp. (2003–2008)
Asset resilience ratio of Resverlogix Corp. from 2003 to 2008. This chart shows how Resverlogix Corp.'s Asset Resilience Ratio has changed over time. Read Resverlogix Corp. (RVX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Resverlogix Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Resverlogix Corp. (RVX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$189.49 | 0.0% |
| Total Liquid Assets | CA$189.49 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Resverlogix Corp. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Resverlogix Corp. Industry Peers by Asset Resilience Ratio
Compare Resverlogix Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Resverlogix Corp. Asset Resilience Ratio by Year (2003–2008)
Resverlogix Corp. asset resilience ratio by year from 2003 to 2008. The table below shows the annual Asset Resilience Ratio data for Resverlogix Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2008-12-31 | 0.00% | CA$170.88 ≈ $123.61 |
CA$18.91 Million ≈ $13.68 Million |
-74.97pp |
| 2007-12-31 | 74.97% | CA$15.53 Million ≈ $11.23 Million |
CA$20.71 Million ≈ $14.98 Million |
+1.62pp |
| 2006-12-31 | 73.34% | CA$11.00 Million ≈ $7.96 Million |
CA$15.00 Million ≈ $10.85 Million |
+21.87pp |
| 2005-12-31 | 51.47% | CA$4.15 Million ≈ $3.00 Million |
CA$8.06 Million ≈ $5.83 Million |
+22.88pp |
| 2004-12-31 | 28.60% | CA$2.92 Million ≈ $2.11 Million |
CA$10.20 Million ≈ $7.38 Million |
-49.39pp |
| 2003-12-31 | 77.99% | CA$2.10 Million ≈ $1.52 Million |
CA$2.69 Million ≈ $1.95 Million |
-- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more